Relationship between Serum Fetuin-B Level and Metabolic Parameters in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

Abstract

Aim: Fetuin-B, which is part of the fetuin family, has been demonstrated to be related with the emergence of insulin resistance. Here, we examined the relationship between metabolic parameters in treatment-naive patients with diabetes and fetuin B levels in serum. Material and Method: Individuals aged 30-65 years old who were diagnosed with newly diagnosed diabetes mellitus, had no chronic disease history, and provided informed consent were enrolled in the study. The clinical parameters were examined. Results: Forty recently diagnosed type 2 diabetic individuals and 43 controls were analyzed in this study. A significant difference was displayed for waist circumference, serum high-density lipoprotein, low-density lipoprotein, alanine transaminase, homeostatic model assessment for insulin resistance, high-sensitivity C-reactive protein, and carotid intima-media thickness (CIMT) between the two groups. The level of serum fetuin-B was determined to be statistically significantly reduced in diabetic patients compared to that in the serum of the controls. In the diabetic group, we showed a negative correlation between CIMT and fetuin-B (p=0.035). Conclusion: Fetuin-B levels were considerably lower in recently diagnosed type 2 diabetics as equated with those in the control group who had normal glucose levels. Additionally, an inverse association between CIMT and fetuin-B levels among individuals with recently diagnosed type 2 diabetes mellitus.

Keywords

• Carotid intima-media thickness
• fetuin-B
• metabolic parameters
• type 2 diabetes mellitus

Kaynakça

1. Htay T, Soe K, Lopez-Perez A, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. Curr Cardiol Rep. 2019;21:45.
2. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241:2035-8.
3. Darabian S, Hormuz M, Latif MA, et al. The role of carotid intimal thickness testing and risk prediction in the development of coronary atherosclerosis. Curr Atheroscler Rep. 2013;15:306.
4. Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the american society of echocardiography carotid intima-media thickness task force endorsed by the society for vascular. J Am Soc Echocardiogr. 2008;21:93-190. Erratum in: J Am Soc Echocardiogr. 2008;21:376.
5. Olivier E, Soury E, Ruminy P, et al. Fetuin-B, a second member of the fetuin family in mammals. Biochem J. 2000;350:589-97.
6. Liu JX, Zhai YH, Geng FS, et al. Molecular characterization and expression pattern of fetuin-B in gibel carp (Carassius auratus gibelio). Biochem Genet. 2008;46:620-33.
7. Yang F, Schwartz Z, Swain LD, et al. Alpha2-HS-glycoprotein: Expression in chondrocytes and augmentation of alkaline phosphatase and phospholipase A2 activity. Bone. 1991;12:7-15.
8. Chen H, Srinivas PR, Cong LN, et al. Alpha2-Heremans Schmid glycoprotein inhibits insulin-stimulated Elk-1 phosphorylation, but not glucose transport, in rat adipose cells. Endocrinology. 1998;139:4147-54.

9. Ohnishi T, Nakamura O, Arakaki N, Daikuhara Y. Effect of phosphorylated rat fetuin on the growth of hepatocytes in primary culture in the presence of human hepatocyte-growth factor. Evidence that phosphorylated fetuin is a natural modulator of hepatocyte-growth factor. Eur J Biochem. 1997;243:753-61.
10. Wang H, Zhang M, Bianchi M, et al. Fetuin (α2-HS-glycoprotein) opsonizes cationic macrophage-deactivating molecules. Proc Natl Acad Sci U S A. 1998;95:14429-34.
11. Almarashda O, Abdi S, Yakout S, et al. Hepatokines fetuin-A and fetuin-B status in obese Saudi patient with diabetes mellitus type 2. Am J Transl Res. 2022;14:3292-302.
12. Peter A, Kovarova M, Staiger H, et al. The hepatokines fetuin-A and fetuin-B are upregulated in the state of hepatic steatosis and may differently impact on glucose homeostasis in humans. Am J Physiol Endocrinol Metab. 2018;314:E266-73.
13. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41:S13-27.
14. Li L, Spranger L, Stobäus N, et al. Fetuin-B, a potential link of liver-adipose tissue cross talk during diet-induced weight loss–weight maintenance. Nutr Diabetes. 2021;11:31.
15. Wang D, Liu Y, Liu S, et al. Serum fetuin-B is positively associated with intrahepatic triglyceride content and increases the risk of insulin resistance in obese Chinese adults: A cross-sectional study. J Diabetes. 2018;10:581-8.
16. Pasmans K, Goossens GH, Groenhuijzen E, et al. Fetuin B in white adipose tissue induces inflammation and is associated with peripheral insulin resistance in mice and humans. Obesity. 2024;32:517-27.
17. Xia X, Xue S, Yang G, et al. Association of serum fetuin-B with insulin resistance and pre-diabetes in young Chinese women: evidence from a cross-sectional study and effect of liraglutide. PeerJ. 2021;9:e11869.
18. Qu H, Qiu Y, Wang Y, et al. Plasma fetuin-B concentrations are associated with insulin resistance and first-phase glucose-stimulated insulin secretion in individuals with different degrees of glucose tolerance. Diabetes Metab. 2018;44:488-92.
19. Zhu J, Wan X, Wang Y, et al. Serum fetuin B level increased in subjects of nonalcoholic fatty liver disease: a case-control study. Endocrine. 2017;56:208-11.
20. El-Ashmawy HM, Ahmed AM. Serum fetuin-B level is an independent marker for nonalcoholic fatty liver disease in patients with type 2 diabetes. Eur J Gastroenterol Hepatol. 2019;31:859-64.
21. Li Z, Lin M, Liu C, et al. Fetuin-B links nonalcoholic fatty liver disease to type 2 diabetes via inducing insulin resistance: Association and path analyses. Cytokine. 2018;108:145-50.
22. Yakout SM, Hussein S, Al-Attas OS, et al. Hepatokines fetuin A and fetuin B status in women with/without gestational diabetes mellitus. Am J Transl Res. 2023;15:1291-9.
23. Li Z, He C, Liu Y, et al. Association of fetuin-b with subclinical atherosclerosis in obese chinese adults. J Atheroscler Thromb. 2020;27:418-28.
24. Hou J, Deng Q, Liu S, et al. Plasma proteome profiling of patients with in-stent restenosis by tandem mass tag-based quantitative proteomics approach. Front Cardiovasc Med. 2022;9:793405.